Fred Hutch researchers have created a gene-expression map of glial cells of the tiny worm, C. elegans, adding the missing ...

Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Three major Mount Sinai research studies offer new hope for patients facing chronic lymphocytic leukemia (CLL), a rare type ...

SGR-1505 was designed using Schrödinger's computational platform at scale and was discovered approximately 10 months after the company started its MALT1 program. A Phase 1 study in patients with ...

Panelists discuss the future of Bruton tyrosine kinase (BTK) inhibitor therapies, considering emerging treatments, regulatory changes, evolving cost dynamics, and the current unmet needs in chronic ...

Innovent Biologics is pivoting to R&D and oncology growth in China, but high valuation and risks temper upside. Read why ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued ...

New trial results reveal BGB-16673's promising safety and efficacy in treating relapsed CLL/SLL, showing significant ...

GEO-CM04S1 demonstrated significantly enhanced T cell responses, specifically IFN-γ secretion and activation-induced markers (AIM+), compared to a matched cohort receiving an authorized mRNA ...

Discover why BeOne Medicines (BEIGF) is a strong Buy with growth driven by Brukinsa, Tevimbra, and a promising oncology pipeline.

Investigators confirmed the safety and efficacy outcomes of a total of 3 CD19-directed chimeric antigen receptor (CAR) T-cell therapies with other real-world data with CAR T-cell therapy in patients ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association ...